Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Sosei Group is not ready to give up on its fibromyalgia candidate AD 337 after a Phase II study failed to meet its primary endpoint, the firm announced Sept. 18

You may also be interested in...



Sosei’s Cancer Breakthrough Pain Drug Moves Step Closer To Market

TOKYO - Sosei has started Phase III studies in Europe for its novel fentanyl sublingual spray AD 923, an opiod analgesic used for the treatment of cancer breakthrough pain, the Tokyo-based biopharmaceutical company announced Feb. 12

Sosei’s Cancer Breakthrough Pain Drug Moves Step Closer To Market

TOKYO - Sosei has started Phase III studies in Europe for its novel fentanyl sublingual spray AD 923, an opiod analgesic used for the treatment of cancer breakthrough pain, the Tokyo-based biopharmaceutical company announced Feb. 12

Cymbalta Fibromyalgia sNDA Could Make Lilly Product Lyrica’s First Competitor

Patients treated with Cymbalta show greater reduction in pain compared to placebo in a six-month pivotal trial, Lilly reports.

Related Content

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel